Caribou Biosciences (NASDAQ:CRBU) Posts Earnings Results, Beats Expectations By $0.08 EPS

Caribou Biosciences (NASDAQ:CRBU) announced its quarterly earnings data on Wednesday. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.08, FiscalAI reports. Caribou Biosciences had a negative return on equity of 84.17% and a negative net margin of 1,189.14%.The firm had revenue of $1.50 million for the quarter, compared to analyst estimates of $2.28 million.

Caribou Biosciences Stock Performance

CRBU stock opened at $1.55 on Friday. Caribou Biosciences has a one year low of $1.38 and a one year high of $3.54. The stock has a market capitalization of $154.22 million, a P/E ratio of -1.10 and a beta of 2.38. The company has a 50 day moving average price of $1.69 and a two-hundred day moving average price of $1.84.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on CRBU shares. HC Wainwright lifted their target price on shares of Caribou Biosciences from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Caribou Biosciences in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.67.

Institutional Trading of Caribou Biosciences

A number of hedge funds have recently added to or reduced their stakes in CRBU. Millennium Management LLC boosted its holdings in Caribou Biosciences by 107.4% in the third quarter. Millennium Management LLC now owns 3,216,535 shares of the company’s stock valued at $7,495,000 after acquiring an additional 1,665,946 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Caribou Biosciences by 110.1% in the 4th quarter. Renaissance Technologies LLC now owns 1,639,857 shares of the company’s stock worth $2,607,000 after purchasing an additional 859,436 shares during the last quarter. Marshall Wace LLP boosted its stake in Caribou Biosciences by 600.2% during the 4th quarter. Marshall Wace LLP now owns 881,105 shares of the company’s stock valued at $1,401,000 after purchasing an additional 755,261 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in Caribou Biosciences by 136.1% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 824,299 shares of the company’s stock valued at $1,311,000 after acquiring an additional 475,216 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in Caribou Biosciences by 741.6% in the first quarter. AQR Capital Management LLC now owns 525,878 shares of the company’s stock worth $480,000 after purchasing an additional 463,391 shares during the period. 77.51% of the stock is owned by institutional investors and hedge funds.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.